Global CRISPR Gene Editing Therapies Market Size Likely to Grow at a CAGR of 12.9% By 2035

The CRISPR gene editing therapies market is projected to grow from USD 4.71 billion in 2026 to USD 18.96 billion by 2035 at a CAGR of 14.9% from 2026 to 2035.

CRISPR Gene Editing Therapies Market Revenue and Trends

The global market for CRISPR gene editing therapies includes novel therapeutics based on CRISPR-Cas9 and emerging gene editing techniques that precisely edit DNA to treat genetic diseases, hematological disorders, oncology, rare diseases, and other disease areas. These therapies can correct, remove, or insert genes to correct the underlying cause of this inherited blinding disease, sickle cell disease, beta-thalassemia, and other diseases. The global market for CRISPR gene editing therapies is expanding at a rapid pace as numerous therapies are being approved for clinical use, increased funding in gene therapy pipelines, rising incidence of genetic diseases, and increasing application of gene editing technologies in the delivery of personalized medical treatments globally.

What are the Factors That Have a Significant Contribution to the Growth of the CRISPR gene editing therapies market?

Global interest in precision medicine, promising clinical results and regulatory achievements, including the approval of Casgevy, have accelerated uptake of the treatments, viewing them as a novel approach to longstanding and difficult-to-treat genetic conditions. The market is seeing steady advancement in clinical pipelines and growing patient and physician engagement with one-time potentially curative treatments, per industry reports. With the knowledge of these genetic diseases and the possibilities of CRISPR increasing, healthcare providers and patients are looking for more advanced gene editing therapies to be complementary with other treatments and to help them manage or cure the disease in the long term.

Technological improvements have brought more precise CRISPRs, new generation base and prime editing, new viral and non-viral delivery systems, and new safety profiles, which have reduced off-target effects and increased therapeutic efficacy. Other factors are increased awareness of rare and orphan diseases, greater availability of advanced therapies in emerging markets, government efforts and significant investments in gene editing R&D and commercialization in both developed and emerging markets by venture capital and industry.

Segment Insight

By Product Type

In terms of market share, as of 2025, the ex vivo CRISPR therapies market accounted for the largest share, driven by its well-established clinical success, including approved therapies for sickle cell disease and beta-thalassemia, as well as its high level of efficacy and safety in hematological applications. Innovations in these treatments have seen significant advancement in precision of editing and manufacturing scalability, making them more easily accessible and effective, especially for hematologists, geneticists and regulatory experts, who see these as vital to safe and effective gene correction in severe genetic disorders that may only require one treatment.

By Distribution Channel

Direct sales and specialized healthcare providers/hospitals constitute the biggest market share, as they are the main ones through which therapy is administered, patients are selected, specialized treatment centers, and full medical support is provided. With their specialized expertise in clinical advice, regulatory adherence, and post-treatment oversight, these channels are the ideal solution for healthcare institutions and specialized centers conducting advanced personalized gene editing procedures.

Regional Insights

North America is home to the majority of the global gene editing therapies market as the region has experienced a significant investment in research and development, the presence of key CRISPR companies, advanced biotechnology infrastructure, high R&D funding, and approval of the first therapies in the region. The region receives significant investments, promising reimbursement reforms, and a vibrant clinical trial environment that inspires ongoing innovation and market stability.

The Asia Pacific region is showing the highest growth rate in the CRISPR gene editing therapies market, due to the increasing government funding in biotechnology, the prevalence of genetic disorders, healthcare investments, and the increase in clinical research capacity. In countries such as China, Japan, and India, the use of gene editing research and therapy is growing, with biotechnology advances and progress in regulations, along with a focus on precision medicine. The increasing partnerships, healthcare facilities expansion and demand for innovative therapeutic solutions are contributing to market's growth in Asia Pacific.

Report Scope

Recent Developments

• In 2025: CRISPR Therapeutics continued to make strides forward, exciting progress in its pipeline fueled by further clinical trial data and enhanced partnerships for next-generation CRISPR therapies beyond hematology, continuing its path as a leader in transformative gene editing treatments.

List of the prominent players in the CRISPR Gene Editing Therapies Market:

• CRISPR Therapeutics AG

• Vertex Pharmaceuticals Incorporated

• Intellia Therapeutics Inc.

• Editas Medicine Inc.

• Beam Therapeutics Inc.

• Prime Medicine Inc.

• Caribou Biosciences Inc.

• Allogene Therapeutics Inc.

• Verve Therapeutics Inc.

• Precision BioSciences Inc.

• Others

The CRISPR Gene Editing Therapies Market is segmented as follows:

By Type

• Ex Vivo CRISPR Therapies

  • Autologous Ex Vivo CRISPR Cell Therapies

  • Allogeneic Off-the-Shelf CRISPR Cell Therapies

  • CRISPR-Edited Hematopoietic Stem Cell Therapies

  • CRISPR-Edited CAR-T Cell Therapies

• In Vivo CRISPR Therapies

  • Systemic In Vivo CRISPR Therapies (LNP-delivered)

  • Locally Administered In Vivo CRISPR Therapies (AAV-delivered)

  • In Vivo Base Editing Therapies

  • In Vivo Prime Editing Therapies

By Technology

• CRISPR-Cas9

  • Wildtype SpCas9-Based Therapies

  • High-Fidelity Cas9 Variants (eSpCas9, HiFi Cas9)

  • Compact Cas9 Orthologs (SaCas9, CjCas9)

• CRISPR-Cas12

  • Cas12a (Cpf1)-Based Therapies

  • Cas12b-Based Systems

• CRISPR-Cas13

  • RNA-Targeting Cas13-Based Therapies

  • Cas13-Based Diagnostics & Therapeutic Hybrids

• Base Editing

  • Adenine Base Editors (ABE)

  • Cytosine Base Editors (CBE)

  • Dual Base Editors

• Prime Editing

  • PE2 and PE3 Prime Editing Systems

  • Epigenome Editing via Prime Editing

• Other Technologies

  • Epigenome Editing (CRISPRa/CRISPRi)

  • CRISPR-Associated Transposons (CAST)

  • Paired Nickase Systems

By Application

• Genetic Disorders

  • Hemoglobinopathies (Sickle Cell Disease & Beta-Thalassemia)

  • Duchenne Muscular Dystrophy (DMD)

  • Familial Hypercholesterolemia

  • Alpha-1 Antitrypsin Deficiency

  • Transthyretin Amyloidosis (ATTR)

  • Cystic Fibrosis

  • Other Rare Genetic Disorders

• Oncology

  • Hematological Malignancies (AML, ALL, Multiple Myeloma)

  • Solid Tumors (Lung, Liver, Pancreatic Cancer)

  • CRISPR-Enhanced CAR-T Therapies

  • CRISPR-Enabled Neoantigen Therapies

• Infectious Diseases

  • HIV/AIDS CRISPR Eradication Programs

  • Hepatitis B Virus (HBV) Functional Cure

  • HPV-Associated Disease

  • Emerging Viral Disease Programs

• Ophthalmology

  • Leber Congenital Amaurosis (LCA10)

  • Usher Syndrome

  • Age-Related Macular Degeneration (AMD)

• Cardiovascular Diseases

  • PCSK9 Inactivation for LDL Reduction

  • Angiopoietin-Like Protein 3 (ANGPTL3) Editing

  • Lipoprotein(a) Reduction Programs

• Other Applications

  • Central Nervous System Disorders

  • Autoimmune & Inflammatory Diseases

  • Metabolic Liver Diseases

By Delivery Mechanism

• Viral Vectors

  • Adeno-Associated Virus (AAV) Vectors

  • Lentiviral Vectors

  • Adenoviral Vectors

• Lipid Nanoparticles (LNP)

  • Ionizable LNP Systems

  • Organ-Selective LNP (SORT Technology)

  • PEGylated LNP Formulations

• Ribonucleoproteins (RNP)

  • Electroporation-Mediated RNP Delivery

  • Cell-Penetrating Peptide-RNP Conjugates

• Other Delivery Mechanisms

  • Extracellular Vesicles & Exosomes

  • Polymeric Nanoparticles

  • Hydrodynamic Delivery

By End Use

• Hospitals & Specialty Clinics

  • Authorized Treatment Centers (ATCs) for Approved CRISPR Therapies

  • Hematology & Oncology Specialty Centers

  • Rare Disease & Metabolic Disease Centers

• Academic & Research Institutions

  • University Research Laboratories

  • Government-Funded Research Institutes

  • Clinical Research Organizations (CROs)

• Biotechnology & Pharmaceutical Companies

  • Dedicated CRISPR Therapy Biotechs

  • Big Pharma CRISPR Licensing & Co-Development Programs

  • Gene Therapy CDMOs

• Other End Users

  • Patient Advocacy & Compassionate Use Programs

  • Agricultural & Industrial CRISPR Applications

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America